CN105535009A - 一种预防和治疗听力损失的药物或保健品 - Google Patents
一种预防和治疗听力损失的药物或保健品 Download PDFInfo
- Publication number
- CN105535009A CN105535009A CN201610055028.4A CN201610055028A CN105535009A CN 105535009 A CN105535009 A CN 105535009A CN 201610055028 A CN201610055028 A CN 201610055028A CN 105535009 A CN105535009 A CN 105535009A
- Authority
- CN
- China
- Prior art keywords
- hearing loss
- medicine
- health product
- health care
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011878 Deafness Diseases 0.000 title claims abstract description 76
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 75
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 72
- 230000010370 hearing loss Effects 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 230000036541 health Effects 0.000 title claims abstract description 39
- 229940079593 drug Drugs 0.000 title abstract description 10
- 206010011891 Deafness neurosensory Diseases 0.000 claims abstract description 18
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims abstract description 18
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims abstract description 18
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims abstract description 16
- 206010011903 Deafness traumatic Diseases 0.000 claims abstract description 11
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims abstract description 11
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 22
- 208000023088 sudden sensorineural hearing loss Diseases 0.000 claims description 6
- 108010025076 Holoenzymes Proteins 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 15
- 206010061373 Sudden Hearing Loss Diseases 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 39
- 241000700199 Cavia porcellus Species 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 4
- 206010010280 Conductive deafness Diseases 0.000 description 4
- 206010013886 Dysaesthesia Diseases 0.000 description 4
- 208000023563 conductive hearing loss disease Diseases 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010036626 Presbyacusis Diseases 0.000 description 3
- 235000014590 basal diet Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 231100000895 deafness Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 208000009800 presbycusis Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000000860 cochlear nerve Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 1
- 238000012076 audiometry Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000022949 middle ear disease Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610055028.4A CN105535009A (zh) | 2016-01-27 | 2016-01-27 | 一种预防和治疗听力损失的药物或保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610055028.4A CN105535009A (zh) | 2016-01-27 | 2016-01-27 | 一种预防和治疗听力损失的药物或保健品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535009A true CN105535009A (zh) | 2016-05-04 |
Family
ID=55814935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610055028.4A Pending CN105535009A (zh) | 2016-01-27 | 2016-01-27 | 一种预防和治疗听力损失的药物或保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535009A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108309964A (zh) * | 2018-04-04 | 2018-07-24 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 二甲双胍在制备噪声性听力损失防治产品中的应用 |
WO2019028877A1 (zh) * | 2017-08-11 | 2019-02-14 | 邦泰生物工程(深圳)有限公司 | 一种含有nadh和nadph的组合物及其应用 |
WO2019054485A1 (ja) * | 2017-09-14 | 2019-03-21 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
JPWO2018052020A1 (ja) * | 2016-09-13 | 2019-06-24 | めぐみ 田中 | 睡眠障害改善剤及び睡眠障害の改善方法 |
WO2020054795A1 (ja) * | 2018-09-14 | 2020-03-19 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080318892A1 (en) * | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
CN104758307A (zh) * | 2015-03-16 | 2015-07-08 | 邦泰生物工程(深圳)有限公司 | Nadh和nmn在制备帕金森病药物或保健品的应用 |
-
2016
- 2016-01-27 CN CN201610055028.4A patent/CN105535009A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080318892A1 (en) * | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
CN104758307A (zh) * | 2015-03-16 | 2015-07-08 | 邦泰生物工程(深圳)有限公司 | Nadh和nmn在制备帕金森病药物或保健品的应用 |
Non-Patent Citations (1)
Title |
---|
CHARLES BRENNER: "Boosting NAD to Spare Hearing", 《CELL METABOLISM》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2018052020A1 (ja) * | 2016-09-13 | 2019-06-24 | めぐみ 田中 | 睡眠障害改善剤及び睡眠障害の改善方法 |
WO2019028877A1 (zh) * | 2017-08-11 | 2019-02-14 | 邦泰生物工程(深圳)有限公司 | 一种含有nadh和nadph的组合物及其应用 |
CN109562120A (zh) * | 2017-08-11 | 2019-04-02 | 邦泰生物工程(深圳)有限公司 | 一种含有nadh和nadph的组合物及其应用 |
WO2019054485A1 (ja) * | 2017-09-14 | 2019-03-21 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
JPWO2019054485A1 (ja) * | 2017-09-14 | 2020-10-15 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
JP7210459B2 (ja) | 2017-09-14 | 2023-01-23 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
CN108309964A (zh) * | 2018-04-04 | 2018-07-24 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 二甲双胍在制备噪声性听力损失防治产品中的应用 |
CN108309964B (zh) * | 2018-04-04 | 2020-06-30 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 二甲双胍在制备噪声性听力损失防治产品中的应用 |
WO2020054795A1 (ja) * | 2018-09-14 | 2020-03-19 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
CN112739222A (zh) * | 2018-09-14 | 2021-04-30 | 田中惠 | 抗衰老剂以及抗衰老方法 |
JPWO2020054795A1 (ja) * | 2018-09-14 | 2021-08-30 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105535009A (zh) | 一种预防和治疗听力损失的药物或保健品 | |
Skarzynski et al. | Partial deafness cochlear implantation in children | |
Ottaviani et al. | Absence of otoacoustic emissions in insulin-dependent diabetic patients: is there evidence for diabetic cochleopathy? | |
Singh et al. | Vestibular evoked myogenic potentials in children with sensorineural hearing loss | |
Philibert et al. | The auditory acclimatization effect in sensorineural hearing-impaired listeners: evidence for functional plasticity | |
NZ593364A (en) | Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture | |
Liu et al. | Effect of age at cochlear implantation on auditory and speech development of children with auditory neuropathy spectrum disorder | |
NZ593365A (en) | Pharmaceutical preparation comprising a blood mononuclear cell culture | |
Salami et al. | Water-soluble coenzyme Q10 formulation (Q-TER®) in the treatment of presbycusis | |
Turner et al. | Exposure to an augmented acoustic environment alters auditory function in hearing-impaired DBA/2J mice | |
Meena et al. | Evaluation of hearing loss in patients with type 2 diabetes mellitus | |
Sheppard et al. | Auditory central gain compensates for changes in cochlear output after prolonged low-level noise exposure | |
Sliwinska-Kowalska | Hearing | |
CN105456286A (zh) | 烟酰胺单核苷酸在制备用于防治听力损失的药物或保健品中的应用 | |
Fowler et al. | Hyperinsulinemia/diabetes, hearing, and aging in the University of Wisconsin calorie restriction monkeys | |
Ramsden et al. | Parental and program's decision making in paediatric simultaneous bilateral cochlear implantation: Who says no and why? | |
Verma et al. | Audiovestibular dysfunction in alcohol dependence. Are we worried? | |
Kumar et al. | Audiological profile in patients with hypothyroidism and hyperthyroidism | |
Abrar et al. | Simultaneous bilateral cochlear implantation under local anaesthesia in a visually impaired adult with profound sensorineural deafness: a case report | |
Toprak et al. | Astaxanthin protects against hearing impairment in diabetic rats | |
Pawlak-Osinska et al. | Episodes of repeated sudden deafness following pregnancies | |
Liang et al. | The effects and outcomes of electrolyte disturbances and asphyxia on newborns hearing | |
Reynard et al. | Paradoxical and labile medial olivocochlear functioning as a potential marker of auditory processing disorder in a child with learning disabilities | |
CN104546815A (zh) | 丁酸钠的预防噪声性听力损伤的应用 | |
KR20000076874A (ko) | 케모카인 생산 촉진제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171023 Address after: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Applicant after: Hongbo Yuan Technology (Shenzhen) limited life Address before: 518102, Guangdong, Shenzhen, Xixiang Baoan District Gang Gang the Peach Garden science and Technology Innovation Park third points garden, 1 Factory Building 1 layer A-2 Applicant before: Bontac Bio-engineering (Shenzhen) Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160504 |
|
WD01 | Invention patent application deemed withdrawn after publication |